Prior research established that CD4 memory resting T cells can be further differentiated and confer a variety of functions, including inhibiting CD8+ T cell activation and NK cell killing, suppressing harmful immune responses to self- and foreign antigens, and assisting CD8+ T cells in tumor rejection. The gene discussed is CD8A; the disease is neoplasm.